MorphoSys AG Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
Published: Mar 06, 2012
MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - March 06, 2012) -
MorphoSys AG /
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Study Data Expected in Q3 2012
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the successful completion of patient enrollment in its phase 1b/2a clinical trial evaluating MOR103, a HuCAL antibody targeting GM-CSF (granulocyte macrophage- colony stimulating factor). 96 patients with active rheumatoid arthritis (RA) have been randomized in the double-blind, placebo-controlled study at various clinical centers in Europe to evaluate the safety and preliminary signs of clinical activity of MOR103 when administered intravenously in multiple doses. Data from the trial will become available in Q3 2012.
"Within the past months, MorphoSys's entire proprietary portfolio has advanced significantly," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We currently have four proprietary programs in clinical trials, all of them targeting novel or better treatment options for severe diseases. We are well on track to expect a whole range of exciting news from our own development portfolio in the years to come. GM-CSF is strongly implicated in the pathogenesis of inflammatory diseases, including rheumatoid arthritis. Data generated with an antibody targeting the GM-CSF receptor last year provided further clinical validation of the GM-CSF pathway in RA."
In addition to the RA study, MOR103 is currently being evaluated in two additional clinical trials. Patient enrollment in a phase 1b dose- escalation study in multiple sclerosis began in early 2012. A phase 1 pharmacokinetic study in healthy volunteers to evaluate a subcutaneous formulation of MOR103 will recruit the final cohort shortly. Subcutaneous injection represents a more convenient route of administration for patients and the data will help guide dosing regimens for future clinical trials for MOR103.
In total, MorphoSys currently has four proprietary clinical programs ongoing, including MOR103 in RA and MS, as well as MOR202, a HuCAL antibody targeting CD38, in multiple myeloma and MOR208, an Fc-enhanced humanized antibody targeting CD19, in chronic lymphocytic leukemia and other B-cell malignancies.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a Therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Media Release (PDF): http://hugin.info/130295/R/1591474/500206.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
For more information, please contact:
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332